28 October 2025
Latham & Watkins Advises on MapLight Therapeutics’ Initial Public Offering
Advising firms
Deal team
6 lawyers named| Lawyer | Firm | Seniority | Practice | Office |
|---|---|---|---|---|
| Nathan Ajiashvili Lead | Latham & Watkins LLP | Partner | Capital Markets | New York |
| Matt Bush | Latham & Watkins LLP | Partner | Capital Markets | San Diego |
| Sandy Kugbei | Latham & Watkins LLP | Associate | Capital Markets | Not stated |
| Akina Newbraugh | Latham & Watkins LLP | Associate | Capital Markets | Not stated |
| Kan Ni | Latham & Watkins LLP | Associate | Capital Markets | Not stated |
| Skye Lee | Latham & Watkins LLP | Associate | Capital Markets | Not stated |
3 more lawyers on this deal. Register free to see the full deal team, with seniority, practice and office.
REGISTER FREE SIGN INWant co-counsel patterns, repeat clients and alerts when these firms land their next deal? Get Pro.
Stated terms
- Stated value
- USD 17 (US$17 per share)
- What the figure measures
- Issue size
- Client
- Not stated
- Counterparties
- MapLight Therapeutics, Inc. (Issuer)